Physician profile

Eric Jung

Urology · Los Angeles, CA

NPI 1992153381

$7,186.65

in general payments reported to CMS, 2019-2025

9 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Travel and Lodging$997.60
Food and Beverage$406.94

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Boston Scientific Corporation $2,603.70 2019-2021
Olympus Corporation of The Americas $1,791.71 2019
Procept Biorobotics Corporation $1,404.54 2024 Aquabeam Robotic System
Intuitive Surgical, INC. $516.11 2021
Karl Storz Endoscopy-America $468.33 2019-2020
Cook Incorporated $148.30 2020
Coloplast Corp $129.01 2019
Horizon Therapeutics Plc $78.53 2022
Bausch & Lomb Americas INC. $46.42 2022

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Eric Jung

$7,186.65

in general payments reported 2019-2025

Years
2019-2024
Top company
Boston Scientific Corporation

https://glasscript.com/doctor/1562847/eric-jung

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.